Article
Hematology
Sindy N. Escobar Alvarez, Elizabeth R. Myers
Summary: The Doris Duke Charitable Foundation provided funding for sickle cell disease (SCD) research through the Innovations in Clinical Research Awards program, resulting in substantial advancements in diagnosis and treatment of the disease. The research investment showed substantial financial return and led to significant innovations in the field.
Article
Chemistry, Multidisciplinary
Abhishek Gour, Pankul Kotwal, Ashish Dogra, Dilpreet Kour, Sumit Dhiman, Amit Kumar, Sanjeev Kumar Digra, Ajay Kumar, Gurdarshan Singh, Utpal Nandi
Summary: Andrographolide shows significant antisickling activity and may be a potential adjuvant therapy for sickle cell anemia. However, caution should be taken when used concomitantly with hydroxyurea.
Editorial Material
Hematology
Charles T. Quinn, Russell E. Ware
Summary: This article points out that some women with sickle cell anemia have diminished ovarian reserve and argues for equitable access to fertility preservation strategies, which are offered to women with cancer.
Article
Multidisciplinary Sciences
Zahid Ali, Mohammad Ismail, Inayat Ur Rehman, Gulab Fatima Rani, Muhammad Ali, Muhammad Tariq Masood Khan
Summary: This single-arm, non-randomized clinical trial aimed to explore the long-term safety and efficacy of thalidomide in hydroxyurea refractory transfusion-dependent beta-thalassemia patients. The study found that thalidomide treatment can significantly increase hemoglobin level, reduce transfusion frequency, lower serum ferritin level, and improve liver and spleen size. The results suggest that thalidomide is an effective and well-tolerated drug for improving hemoglobin levels and reducing transfusion burden in TDT patients.
SCIENTIFIC REPORTS
(2023)
Article
Pharmacology & Pharmacy
Paolo Ricchi, Antonella Meloni, Paolo Rigano, Laura Pistoia, Anna Spasiano, Massimo Allo, Giuseppe Messina, Antonella Quarta, Rosamaria Rosso, Alessandra Quota, Aldo Filosa, Aurelio Maggio, Alessia Pepe
Summary: This study evaluated the effects of hydroxyurea (HU) treatment in Italian patients with non-transfusion dependent thalassemia (NTDT). The results showed improvements in hematological indices and a positive impact of HU treatment on limiting the progression of complications associated with NTDT syndrome. The findings suggest that HU may still be a valid option for managing NTDT patients.
EXPERT OPINION ON DRUG SAFETY
(2022)
Article
Genetics & Heredity
Reuben Ikechukwu Chianumba, Akinyemi O. D. Ofakunrin, Jack Morrice, Olaniyi Olanrewaju, Oluseyi Oniyangi, Aisha Kuliya-Gwarzo, Uche Nnebe-Agumadu, Hezekiah Alkali Isa, Obiageli Eunice Nnodu
Summary: This study assessed the perception and experience of SCD patients in Nigeria using or had used HU, revealing that most patients had a positive perception and experience with HU, while some discontinued due to high cost and limited availability.
FRONTIERS IN GENETICS
(2022)
Review
Immunology
Chang Liu, Kun Xiao, Lixin Xie
Summary: Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a critical and high-mortality clinical syndrome. Current treatment mainly focuses on symptomatic therapy, but prognosis is poor. The discovery of exosomes provides a promising perspective for the treatment of ALI/ARDS by exerting anti-inflammatory effects, inhibiting apoptosis, and promoting cell regeneration.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Daniela Mokra, Juraj Mokry, Romana Barosova, Juliana Hanusrichterova, Canhua Huang, Binghua Jiang
Summary: N-acetylcysteine (NAC) is widely used in the treatment of cystic fibrosis and acetaminophen overdosing, and may also be beneficial in other chronic respiratory diseases. It has antioxidative and anti-inflammatory effects, low toxicity, rare adverse effects, and is easily accessible.
Review
Oncology
Xiangnan Teng, Jiali Wu, Jing Liao, Shanling Xu
Summary: ECMO can be used as a supportive means for cancer patients undergoing surgery, those with respiratory failure due to solid tumors, and hematological tumor patients requiring chemotherapy. However, there is no clear benefit in using ECMO for hematologic oncology patients undergoing hematopoietic stem cell transplantation.
Review
Medicine, General & Internal
Yajur Arya, Arshi Syal, Monica Gupta, Saurabh Gaba
Summary: Treatment modalities for polycythemia vera (PV) vary depending on the patient's risk level and symptoms, with options including interferons, hydroxyurea, and anagrelide. Prospective future treatments include a histone deacetylase inhibitor and a murine double minute 2 antagonist.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Medicine, General & Internal
Joachim B. Kunz, Andreas Schlotmann, Andrea Daubenbuechel, Stephan Lobitz, Andrea Jarisch, Regine Grosse, Holger Cario, Lena Oevermann, Dani Hakimeh, Laura Tagliaferri, Andreas E. Kulozik
Summary: The number of patients with Sickle Cell Disease in Germany has increased in recent years, with a significant rise in the use of hydroxyurea treatment. The increased use of hydroxyurea has led to a decrease in the incidence of acute chest syndromes, as well as a reduction in the proportion of patients requiring analgesics and hospital admissions.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Josef Jampilek, Daniela Placha
Summary: Nanomaterials offer a new strategy for the regeneration of bones and cartilage, with the potential to repair and heal damaged tissues. However, they may also induce inflammation processes, highlighting the importance of understanding their effects and implementing surface modifications to mitigate negative impacts.
Review
Nanoscience & Nanotechnology
Elidamar Nunes de Carvalho Lima, Ricardo Sobhie Diaz, Joao Francisco Justo, Jose Roberto Castilho Piqueira
Summary: Nanovaccines utilize nanotechnology to enhance immunogenicity of specific antigens. Carbon nanotubes can act as carriers or immunostimulants, offering characteristics of nonclassical vaccines.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Pediatrics
Asmaa M. Zahran, Khaled Saad, Khalid Elsayh, Shaimaa M. Khalaf, Khaled Hashim Mahmoud, Amira Elhoufey, Helal F. Hetta
Summary: Among children with SCD, HU treatment exhibited significant qualitative and quantitative effects on Tregs. HU treatment in SCD decreases the frequency of Tregs, as well as the levels of the most suppressive Tregs: HLA-DR+, CD39+, and CD69+. At the same time, HU increases the proportion of naive CD45RA+ Tregs. Our study showed the impact of HU therapy on Tregs in children with SCD.
PEDIATRIC RESEARCH
(2022)
Article
Genetics & Heredity
Emmanuel Chide Okocha, Joyce Gyamfi, Nessa Ryan, Oluwatoyin Babalola, Eno-Abasi Etuk, Reuben Chianumba, Maxwell Nwegbu, Hezekiah Isa, Anazoeze Jude Madu, Samuel Adegoke, Uche Nnebe-Agumandu, Biobele Brown, Emmanuel Peprah, Obiageli E. Nnodu
Summary: This study identified various barriers to therapeutic use of hydroxyurea for sickle cell disease within the Nigerian healthcare system, including limited knowledge among healthcare providers, low self-efficacy in prescribing and counseling, perceived patient preferences for traditional medicine, and cost issues. Patient, provider, and health system-level interventions are needed to improve hydroxyurea uptake among providers and adherence among patients in Nigeria.
FRONTIERS IN GENETICS
(2022)